IOBT - IO Biotech collaborates with Merck to evaluate IO102-IO103 + Keytruda in three tumor types

IO Biotech (NASDAQ:IOBT) has entered into a third clinical trial collaboration and supply agreement with Merck (NYSE:MRK), through a subsidiary. IOBT shares down 11.5% premarket at $9.65. The purpose of the collaboration is to evaluate the safety and efficacy of IO Biotech’s IO102-IO103, in combination with MRK's Keytruda (pembrolizumab), in previously untreated patients with metastatic non-small cell lung cancer, squamous cell carcinoma of the head and neck, and metastatic urothelial bladder cancer. Additional correlative endpoints will also be explored to elucidate the mechanism of action. Under the terms of the agreement, IOBT will sponsor the Phase 2 trial and Merck will supply pembrolizumab. IO Biotech maintains global commercial rights to IO102-IO103.

For further details see:

IO Biotech collaborates with Merck to evaluate IO102-IO103 + Keytruda in three tumor types